Screener / SEC EDGAR /CIK 0001014739 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Home Health Care Services

Option Care Health, Inc. OPCH

Compare with peers Embed
SEC comment letters, last 20 years

7 reviews of OPCH's filings by SEC staff

UPLOAD and CORRESP
Reviews 7 latest letter May 24, 2019
Questions asked 23 each answered in the company's own letter
No closing letter 4 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 8 UPLOAD
  2. 2. Questions in them 23 numbered comments
  3. 3. Company replies 7 CORRESP
  4. 4. Reviews closed 3 of 7 closing letter

Half the closed reviews took 27 days or less from the first letter to the closing letter.

Schedule 14A

2019-05-24 to 2019-06-20 · 11 questions · 1 letter from the SEC, 1 from the company
Review closed 2019-06-20
Income taxesRevenueLiquidity and cashResults discussion (MD&A)
Preliminary Proxy Statement on Schedule 14A Filed April 30, 2019 · General
SEC asked (1)
Please provide pro forma selected financial data for the most recent fiscal year and interim period. Refer to Item 14(b)(9) of Schedule 14A.
OPCH answered
In response to the Staff’s comment, the Company has provided pro forma selected financial data for the three months ended March 31, 2019, beginning on page

127 of the Revised Proxy Statement.
Read in the reply
Preliminary Proxy Statement on Schedule 14A Filed April 30, 2019 · General
SEC asked (2)
Please provide in a table designed to facilitate comparison, historical and pro forma per share data of the acquiring company and historical and equivalent pro forma per share data of the target company for the most recent fiscal year and interim period. Refer to Item 14(b)(10) of Schedule 14A. Unaudited Pro Forma Condensed Combined Financial Statements Notes to Unaudited Pro Forma Combined Financial Information 5.
Rest of the question

Unaudited Pro Forma Combined Balance Sheet Adjustments, page 131

OPCH answered
In response to the Staff’s comment, the Company has provided a table comparing historical and pro forma per share data of the Company and historical and equivalent pro forma per share data of Option Care for the fiscal year ending December 31, 2018 and for the three months ended March 31, 2019, beginning on page 144 of the Revised Proxy Statement and as set forth in Appendix A to this letter.

Unaudited Pro Forma Condensed Combined

Financial Statements

Notes to Unaudited Pro Forma Combined

Financial Information

5. Unaudited Pro Forma Combined Balance Sheet Adjustments,
Read in the reply
Preliminary Proxy Statement on Schedule 14A Filed April 30, 2019 · General
SEC asked (3)
Please use the most recent closing price of Bioscrip’s common stock in your next amendment.
OPCH answered
In response to the Staff’s comment, the Company has revised its disclosure by using the most recent practicable closing price of its common stock on page 134 of the Revised Proxy Statement. The Company advises the Staff that, due to the time required to update the pro forma calculations to reflect the recent closing share price, May 24th, 2019 is the most recent closing price the Company was able to use.
Read in the reply
A. Cash and Cash Equivalents, page 133
SEC asked (4)
We note your adjustment of $124,392 (in thousands) for the settlement of preferred shareholders’ liquidation preference. Please provide a discussion of how this amount was calculated.
OPCH answered
The Company advises the Staff that the amount estimated for cash settlement of preferred shareholders’ liquidation preference was comprised of the liquidation preference as of the most recent balance sheet date, December 31, 2018, adjusted for dividends expected to accrue through the assumed closing date of June 30, 2019, and the 20% premium to be paid in settlement, as defined in the Merger Agreement.

The Company has revised the estimate for cash settlement of preferred shareholders’ liquidation preference included in its Revised Proxy Statement to reflect a new assumed closing date of July
Rest of the answer

31, 2019. As such, the Company has supplemented its disclosure by adding the following footnote 1 on page 136 of the Revised Proxy Statement:

(1) For the amount estimated for cash settlement of preferred shareholders’ liquidation preference, the liquidation preference as of the most recent balance sheet date, March 31, 2019, was adjusted for dividends expected to accrue through an assumed closing date of July 31, 2019 and the 20% premium to be paid in settlement, as defined in the Merger Agreement.

Read in the reply
H. Deferred Income Taxes, page 135
SEC asked (5)
Please revise to disclose the amount of each component of the deferred income taxes and the significant assumptions that were used to calculate each amount.
OPCH answered
In response to the Staff’s comment, the Company has revised the table on page 138 of the Revised Proxy Statement as shown below to disclose the amount of each component of its deferred income taxes as of the balance sheet date of March 31, 2019:

(in thousands)

Option Care

BioScrip

Adjustments for changes in fair value

Adjustments for Valuation Allowance and other

Pro forma Combined

Components of deferred taxes

Bad debt expense

$ 14,879

$ 6,372

$ —

$ 21,251

Interest expense limitation (1)

3,486

12,263

—

13,432

29,181

Net operating losses (1)

10,178

116,549

(8,723
Rest of the answer

)

118,004

Other

9,030

4,823

13,853

Deferred tax assets before valuation allowance

37,573

140,007

4,709

182,289

Fixed assets (2)

(9,483 )

3,679

(5,115 )

(10,919 )

Goodwill and intangibles (2)

(56,430 )

7,853

(59,468 )

1,287

(106,758 )

(1,687 )

(2,049 )

(3,736 )

Deferred tax liabilities

(67,600 )

9,483

(64,583 )

(121,413 )

Less: Valuation allowance (3)

(1,372 )

(148,464 )

78,750

(71,086 )

Net deferred tax (liabilities)/assets

$ (31,399 )

$ 1,026

$ (64,583 )

$ 84,746

$ (10,210 )

(1) Adjustment to historical deferred balance to reflect the impact of the pro forma combined group.

(2) To establish deferred tax liability for increase in basis of acquired fixed assets and intangibles.

(3) Adjustment to the historical balance to reflect the valuation allowance of the pro forma combined group.

Please also refer to the Company's discussion in Comment No. 6, which provides further discussion on valuation allowance changes.

Read in the reply
H. Deferred Income Taxes, page 135
SEC asked (6)
Please revise to disclose how you derived the change in the valuation allowance. In addition, please clarify how the estimated weighted average statutory rate of 26.0% was determined. 6. Statement of Income Adjustments, page 137
OPCH answered
In response to the Staff’s comment, the Company has supplemented the disclosure on page 139 of the Revised Proxy Statement to include the following bolded language related to the valuation allowance changes and weighted average statutory rate:

On a separate company basis, BioScrip was in a net deferred tax asset position with a valuation allowance offsetting the majority of its deferred tax assets, while HC

II was in a net deferred tax liability position.
Rest of the answer

Before considering the need for valuation allowances, the pro forma combined company is in a net deferred tax asset position of approximately $60.9 million. This is primarily driven by BioScrip’s existing deferred tax asset related to net operating losses that exceed the deferred tax liabilities generated from BioScrip’s estimate of additional book to tax differences related to the fair value adjustments for BioScrip’s fixed assets and intangible assets.

The valuation allowances were assessed considering the attributes of specific deferred tax assets and deferred tax liabilities on a pro forma combined basis to determine any required adjustments.

Because of the differences in timing of the reversal of temporary differences comprising the pro forma combined company’s specific deferred tax positions, it was determined that not all of the deferred tax assets would be utilized and therefore a valuation allowance was needed. In addition, there are certain indefinite-lived deferred tax liabilities primarily related to goodwill for which reversal cannot be predicted.

After the consideration of indefinite-lived deferred tax assets, a net deferred tax liability remains after the valuation allowance.

The estimated weighted average statutory rate of 26% was determined by using the federal statutory rate of 21% and the combined estimated state effective rate of 5%, net of federal benefit.

6. Statement of Income Adjustments, page 141

Read in the reply
H. Deferred Income Taxes, page 135
SEC asked (7)
We note from your disclosure beginning on page 50 that you started the discussion and process of the merger in 2018. Please tell us whether you have recorded any transaction expenses in your income statements during the periods presented in your pro forma statements of operations. If so, please explain how you considered adjusting your income statement for these non-recurring costs.
Rest of the question

Refer to Rule 11-02(b)(6) of Regulation S-X. A. Net Revenue, page 137

OPCH answered
The Company advises the Staff that it and HC II both incurred transaction costs during 2018 related to the merger. The Company made adjustments to remove these costs from the unaudited pro forma combined statement of income. Discussion regarding the removal of these non-recurring costs from the pro forma statement of income, including the amount and nature, is included in footnote 6D on page 142 of the Revised Proxy

Statement.
Read in the reply
H. Deferred Income Taxes, page 135
SEC asked (8)
We note that you have recorded an adjustment to remove the adoption of ASC 606 as HC II has not adopted the standard. Please provide us with a detailed discussion to support this adjustment considering HC II will be required to adopt the standard in the near future. C. Interest Expense, page 137
OPCH answered
The Company advises the Staff that, in accordance with the adoption provisions of ASC 606 for nonpublic entities and transition guidance per ASU 2017-13, HC II is required to adopt

ASC 606 in its financial statements for annual periods beginning after December 15, 2018, which will be for HC II’s annual financial statements for the year ended December 31, 2019. As such, HC II has not completed its adoption of ASC 606. HC II will finalize its adoption of ASC 606 in the first interim period subsequent to the completion of the Merger.
Rest of the answer

Since HC II has not yet adopted ASC 606 as of the preparation of the unaudited pro forma combined financial statements, the Company concluded that an adjustment to the Company’s historical income statement to conform with HC II’s policy in accordance with ASC 605 was the most appropriate presentation in order to conform the accounting policies and presentation for the Company and HC II.

In response to the Staff’s comment, the Company has supplemented its disclosure on page 141 of the Revised Proxy Statement to include the following bolded language to explain the expected impact of HC II’s future adoption of ASC 606:

As of January 1, 2018, BioScrip adopted ASC 606, Revenue from Contracts with Customers (“ASC 606”), which differs from HC II’s financial reporting and presentation of revenue as HC II has not yet adopted ASC 606 during the year ended December 31, 2018 and the three months ended March 31, 2019. For pro forma purposes, adjustments are made to increase BioScrip’s net revenue and establish a provision for doubtful accounts to align its revenue recognition policy with that of HC II.

HC II will finalize its adoption of ASC 606 in the first interim period subsequent to completion of the Mergers. HC II believes the adoption of ASC

606 will result in changes to the presentation of the financial information within the consolidated statements of comprehensive income (loss) for estimated variable consideration as well as expanded disclosures within the notes to the financial statements. Similar to BioScrip, the primary change to the consolidated statements of comprehensive income

(loss) will be to the accounting for bad debts. Under the new standard, these amounts are expected to be a direct reduction from net revenues with no impact on net income. HC II anticipates that the decrease in net revenues resulting from the adoption of

ASC 606 will be less than 4% for the three months ended March 31, 2019.

Read in the reply
H. Deferred Income Taxes, page 135
SEC asked (9)
Please disclose the interest rate utilized to calculate the interest expense on the secured senior credit facilities issued in conjunction with the merger and describe how you determined these rates were reasonable.
OPCH answered
In response to the Staff’s comment, the Company has supplemented its disclosure by adding the following bolded language to footnote 2 on page 141 of the Revised Proxy Statement:

(2)

Represents additional interest expense resulting from the refinanced debt instruments in conjunction with the Mergers. The First

Lien Term Loan Facility and Second Lien Notes were issued for $925.0 million and $400.0 million for a duration of 7 years and 8 years, respectively.
Rest of the answer

Interest expense for the Senior Credit Facilities was calculated on an effective interest method, incorporating the impact of expected deferred financing costs, using the following contractual interest rates:

a. First Lien Term Loan Facility: The debt commitment letters stipulate a contractual rate based on either adjusted LIBOR plus 4.5% or ABR plus 3.5% at the option of the borrower, assumed to be 6.9% based on market conditions as of May 24, 2019.

b. Second Lien Notes: The debt commitment letters stipulate a contractual rate equal to the sum of Adjusted LIBOR plus 8.75%, assumed to be 11.3% based on market conditions as of May 24, 2019.

A 1/8 percent variance in interest rates would result in a $1.6 million change to pro forma interest expense for the twelve months ended December 31, 2018 and a $0.4 million change to pro forma interest expense for the three months ended March 31, 2019.

Read in the reply
F. Income Tax (Expense) benefit, page 138
SEC asked (10)
Please revise to disclose the tax effects of the pro forma adjustments based on the statutory rate in effect during the periods presented. If the taxes are calculated utilizing a rate other than the statutory rate, please disclose how you determined the tax rate utilized. Refer to Instruction 7 to paragraph (b) of Rule 11-02 of Regulation S-X.
OPCH answered
In response to the Staff’s comment, the Company reconsidered Instruction 7 to paragraph (b) of Rule 11-02 of Regulation

S-X, and determined that the use of an estimated weighted average statutory rate is the most appropriate rate to use for the pro forma presentation. Accordingly, the Company revised its presentation to record a tax benefit on the pro forma merger adjustments of $2.4 million and a tax benefit on the effects of debt financing of $2.7 million, which are calculated using the estimated weighted average statutory rate of 26.0% multiplied by the pre-tax pro forma merger
Rest of the answer

adjustments of $9.1 million and the pre-tax effects of debt financing of $10.5 million. The Company has revised its disclosure on page 142 of the Revised Proxy Statement to include the following bolded language that discusses the basis of the rate used to calculate tax effects of the pro forma adjustments:

Represents the income tax benefit resulting from the pre-tax pro forma merger adjustments and pre-tax effects of debt financing for the year ended December

31, 2018 and the three months ended March 31, 2019 times the estimated weighted average statutory rate of 26%.

Read in the reply
Liquidity and Capital Resources · Cash Flows from Operating Activities, page 176
SEC asked (11)
We note significant fluctuations in cash provided by operating activities during the periods presented on page 189. Please expand your disclosure to include a robust discussion describing and quantifying the specific effects of the drivers that contributed to the material changes in your operating cash flows for the periods presented.
Rest of the question

The disclosure should also include a discussion of the underlying reasons for changes in working capital items that affect operating cash flows. See guidance in Section IV.B.1 of SEC Release 33-8350.

OPCH answered
In response to the Staff’s comment, the Company has supplemented its disclosure on page 186 of the Revised Proxy Statement to include the following bolded language:

For the twelve months ended December

31, 2018, Option Care generated $24.4 million in positive cash flow from operating activities. This represented a $13.4 million decrease from the $37.9 million generated for the twelve months ended December 31, 2017.
Rest of the answer

The primary drivers of the decline in cash provided by operating activities included: (i) a reduction in accounts payable and accrued expenses and other current liabilities of $32.1 million related to timing of vendor payments in the ordinary course of business; and (ii) an increase in prepaid expenses and other current assets of $17.2 million primarily driven by the timing of vendor rebate payments. Partially offsetting these declines were the following improvements: (i) an improvement in accounts receivable of $13.0 million as Option Care is recovering from the prior year disruption impact of the new pharmacy dispensing system deployment and billing center consolidation; (ii) an improvement in operating income of $11.0 million; (iii) a $6.7 million increase in accrued compensation and employee benefits related to the timing of payroll cycles; and (iv) a $6.4 million reduction in inventory.

Additionally, the Company has supplemented its disclosure on page 187 of the Revised Proxy Statement to include the following bolded language:

31, 2017, Option Care generated $37.9 million in positive cash flow from operating activities, representing a decrease of $48.2 million from the $86.1 million of cash generated from operations for the twelve months ended December 31, 2016. The primary drivers of this decline in cash provided by operating activities included: (i) an increase in accounts receivable of $28.0 million related to the disruption impact from the implementation of a new pharmacy system and billing center consolidation; (ii) the twelve months ended December 31, 2016 included a $27.8 million cash inflow from the strategic reduction of excess inventory levels, which was not repeated in 2017 as balances were at appropriate levels; and (iii) a $25.2 million decline in operating income primarily driven by the impact of the Cures Act. Partially offsetting these declines was an improvement in prepaid expenses and other current assets of $26.2 million related to the timing of vendor rebate payments.

I hope the foregoing has been responsive to the Staff’s comments. Should you have any questions relating to the foregoing, please feel free to contact me at 1 (877)

409-2301.

Read in the reply

Also in this review: closing letter, 2019-06-20

Form 10-K for the Fiscal Year Ended December 31, 2016

2017-08-03 to 2017-08-30 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2017-08-30
Non-GAAP measuresSegments
Result of Operations · Non-GAAP Measures, page 41
SEC asked (1)
We note you provide components of Consolidated Adjusted EBITDA and present “Infusion Services Adjusted EBITDA” and “Corporate Overhead Adjusted EBITDA” which are also presented as non-GAAP financial measures. Please tell us why you believe presenting these components of adjusted EBITDA is useful to investors.
Rest of the question

In this regard, we note that you have only one segment and it does not appear that Infusion Services can be operated autonomously without corporate overhead.

OPCH answered
The Company historically presented the non-GAAP measure “Adjusted EBITDA” for each of its operating segments and its corporate overhead. The Company continued this historical practice even after a number of divestitures left the Company, as the Staff correctly notes, with a single operating segment. After considering the Staff’s comment and following an internal discussion on the utility of continuing to present

Corporate Overhead Adjusted EBITDA, the Company has concluded that it is not necessary to separate those two measures of Adjusted

EBITDA.
Rest of the answer

Going forward, the Company will present only Consolidated Adjusted EBITDA, as illustrated in the proposed reconciliation included in the Company’s response to comment 2.

Read in the reply
In its next report

First report after the company's reply of Aug 15, 2017: 10-Q filed Nov 2, 2017 ↗, against the 10-Q filed May 4, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Result of Operations · Non-GAAP Measures, page 41
SEC asked (2)
Please revise to begin your non-GAAP reconciliation with GAAP results rather than non- GAAP results. See Question 102.10 of the updated Non-GAAP Compliance and Disclosure Interpretations issued on May 17, 2016.
OPCH answered
In future filings and public disclosures, we will revise our reconciliations for Adjusted EBITDA to begin with loss from continuing operations, net of income taxes as the most directly comparable GAAP measure. As an example, included below is the proposed reconciliation for the year ended December

31, 2016, which also incorporates the Company’s change in response to comment 1 above.

BIOSCRIP, INC.
Rest of the answer

AND SUBSIDIARIES

RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES

(in thousands)

Year Ended December 31,

2016

2015

2014

Loss from continuing operations, net of income taxes

(34,367 )

(303,428 )

(149,920 )

Interest expense

38,235

37,313

40,918

Gain on dispositions

(3,954 )

-

Income tax expense

2,015

(21,532 )

11,193

Depreciation and amortization expense

21,551

22,743

22,943

Impairment of goodwill

251,850

Stock-based compensation expense

1,963

4,513

8,570

Change in fiar value of equity linked liabilities

(10,450 )

Restructuring, acquisition, integration, and other expenses, net

15,859

24,405

30,206

Adjusted EBITDA

$ 30,852

$ 15,864

$ (36,090 )

If any of these responses require further clarification, I can be reached at (720) 697-5155 or by email at [email protected].

Respectfully, s/ Stephen M. Deitsch

Stephen

M. Deitsch

Senior Vice President,

Read in the reply
In its next report

First report after the company's reply of Aug 15, 2017: 10-Q filed Nov 2, 2017 ↗, against the 10-Q filed May 4, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2017-08-30

Form S-3

2017-03-30 to 2017-04-13 · 4 questions · 2 letters from the SEC, 1 from the company
No closing letter
General
SEC asked (1)
We note your discussion of a stockholders’ rights plan on page 10. Please revise the fee table to indicate that you are also registering the rights associated with each share of common stock. See Securities Act Forms Question 116.16 of the Division of Corporation Finance’s Compliance and Disclosure Interpretations available at https://www.sec.gov/divisions/corpfin/guidance/safinterp.htm .
Rest of the question

The rights should also be referenced in the opinion of counsel. See Section II.B.1.g. of Staff Legal Bulletin 19, available at https://www.sec.gov/interps/legal/cfslb19.htm .

OPCH answered
The Company respectfully acknowledges the Staff’s comment and has revised the Registration Statement in response. In addition, the opinion of counsel has been revised to reference the rights.
Read in the reply
Incorporation of Documents by Reference, page 2
SEC asked (2)
Please specifically incorporate by reference all reports on Form 8-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of fiscal year covered by your Form 10-K for the fiscal year ended December 31, 2016. See Item 12(a)(2) of Form S-3.
OPCH answered
The Company respectfully acknowledges the Staff’s comment and has revised the Registration Statement in response.

* * * * *

BioScrip acknowledges that:

· the Company is responsible for the adequacy and accuracy of the disclosure in its filings;

· Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

· the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

* * *

If you
Rest of the answer

have any further comments or questions relating to the foregoing, please do not hesitate to contact me (212-698-3616 or [email protected]),

Scott Zimmerman (212-698-3613 or [email protected]) or Jonathan Bush (212-698-3591 or [email protected]).

Read in the reply
SEC letter of Mar 30, 2017 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
General
SEC asked (1)
We note your discussion of a stockholders’ rights plan on page 10. Please revise the fee table to indicate that you are also registering the rights associated with each share of common stock. See Securities Act Forms Question 116.16 of the Division of Corporation Finance’s Compliance and Disclosure Interpretations available at https://www.sec.gov/divisions/corpfin/guidance/safinterp.htm .
Rest of the question

The rights should also be referenced in the opinion of counsel. See Section II.B.1.g. of Staff Legal Bulletin 19, available at https://www.sec.gov/interps/legal/cfslb19.htm .

OPCH answered

No reply letter found.

Incorporation of Documents by Reference, page 2
SEC asked (2)
Please specifically incorporate by reference all reports on Form 8-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of fiscal year covered by your Form 10-K for the fiscal year ended December 31, 2016. See Item 12(a)(2) of Form S-3.
OPCH answered

No reply letter found.

Form S-3

2016-04-08 to 2016-04-28 · 1 question · 1 letter from the SEC, 2 from the company
No closing letter
Where You Can Find More Information, page 2 · Incorporation of Documents by Reference, page 2
SEC asked
We note that you intend to incorporate by reference information required in Part III of your Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Please file the Part III information prior to requesting effectiveness of this registration statement.
Rest of the question

For guidance, see Question 123.01 to the Compliance and Disclosure Interpretations: Securities Act Forms, at http://www.sec.gov/divisions/corpfin/guidance/safinterp.htm.

OPCH answered
The Company respectfully advises the Staff that the Company intends to file, by April 30, 2016, Part III of its Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Such filing will occur by way of incorporation by reference into the Annual Report on Form 10-K from the Company’s definitive proxy statement on Schedule 14A for its 2016 Annual Meeting of Stockholders, or by way of an amendment on Form 10-K/A.
Rest of the answer

The Company confirms it will file the Part III information prior to requesting effectiveness of the Registration

Statement.

* * * * *

The Company acknowledges that: (i) it is responsible for the adequacy and accuracy of the disclosure in the filing; (ii) Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and (iii) the

Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. In addition, the Company hereby confirms that it is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, with respect to the proposed public offering of the securities specified in the Registration Statement.

polsinelli.com

Atlanta Boston Chicago Dallas Denver Houston Kansas City Los Angeles Nashville New York

Phoenix St. Louis San Francisco Washington, D.C. Wilmington

We trust that the information provided in this letter addresses the Staff’s comment. If you have any questions or comments concerning the foregoing, please feel free to telephone the undersigned at (816) 572-4580.

Read in the reply

Also in this review: company letter, Apr 28, 2016

Form S-3

2015-03-20 to 2015-06-24 · 1 question · 1 letter from the SEC, 2 from the company
No closing letter
General
SEC asked
We note that you have incorporated by reference your Form 10-K for the fiscal year ended December 31, 2014 and that your Form 10-K incorporates Part III information by reference to your definitive proxy statement that has not yet been filed. Please be advised that we cannot accelerate the effective date of your registration statement until you file the information required by Part III of Form 10-K.
OPCH answered
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the

Registration Statement effective, the Commission is not foreclosed from taking any action with respect to the Registration Statement;
Read in the reply

Also in this review: company letter, Jun 24, 2015

Form S-4

2015-02-20 to 2015-02-20 · 1 question · 1 letter from the SEC, 0 from the company
No closing letter
Results discussion (MD&A)
SEC letter of Feb 20, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
SEC asked
Under Rule 3-12(b) of Regulation S-X, if the anticipated effective date or proposed mailing date falls after 45 days subsequent to the end of the fiscal year and the registrant does not meet the conditions prescribed under paragraph (c) of Rule 3-01, the filing must include audited financial statements for the most recently completed fiscal year.
Rest of the question

It does not appear from the interim financial information already presented that you could expect to earn net income after taxes but before extraordinary items and cumulative effect of a change in accounting principle. Please update your financial statements and related financial information in accordance with the requirements set forth in Rule 3-12(b) of Regulation S-X, and make consistent revisions to your Management´s Discussion and Analysis of Financial Condition and Results of Operations.

OPCH answered

No reply letter found.

Form 10-K

2013-12-04 to 2013-12-20 · 3 questions · 1 letter from the SEC, 0 from the company
Review closed 2013-12-20
Revenue
SEC letter of Dec 4, 2013 ↗ no reply letter on EDGAR
Item 1. Business · Diversified Payor Base, page 5
SEC asked (1)
We note your disclosure that one payor accounted for 18% of consolidated revenue during the year ended December 31, 2012. Please revise your disclosure to identify this entity as required by Item 101(c)(vii) of Regulation S-K.
OPCH answered

No reply letter found.

In its next report

First report after the SEC's letter of Dec 4, 2013: 10-K filed Mar 3, 2014 ↗.

No earlier 10-K before the SEC's letter is in Tickdelta, so there is nothing to compare with.

Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K, page 96
SEC asked (2)
Please file your Employment Letter Agreement and Severance Agreement with David Evans and your Employment Letter Agreement with Vito Ponzio, Jr. as exhibits pursuant to Item 601(10)(b)(iii)(A) of Regulation S-K. Please also revise your exhibit index to incorporate by reference your Engagement Letter with Hai Tran.
OPCH answered

No reply letter found.

In its next report

First report after the SEC's letter of Dec 4, 2013: 10-K filed Mar 3, 2014 ↗.

No earlier 10-K before the SEC's letter is in Tickdelta, so there is nothing to compare with.

Signatures, page 102
SEC asked (3)
Please amend your Form 10-K to include the signature of your principal accounting officer, Patricia Bogusz, as required by General Instruction D(2) to Form 10-K.
OPCH answered

No reply letter found.

Also in this review: closing letter, 2013-12-20

Letters without questions

Other letters

UPLOAD and CORRESP
7 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 25 letters filed since 2013-12-04. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OPCH/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.